Cellectis News

Cellectis | 20-F: Registration statement / Annual report / Transition report

Apr 29 17:06 ET

Cellectis | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Apr 22 16:37 ET

Cellectis | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Apr 10 16:39 ET

Cellectis | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Apr 8 16:38 ET

Cellectis | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-LONG FOCUS CAPITAL MANAGEMENT, LLC(6.3%),JOHN B. HELMERS(6.3%), etc.

Feb 14 17:27 ET

Cellectis | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-PFIZER INC.(3.89%),Pfizer OTC B. V. N/A(3.89%)

Feb 14 14:28 ET

Cellectis | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Jan 16 00:00 ET

Cellectis | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Dec 22, 2023 16:35 ET

Cellectis | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Dec 22, 2023 16:01 ET

Cellectis | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Dec 5, 2023 16:01 ET

Cellectis | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Baillie Gifford & Co (Scottish partnership)(3.06%)

Dec 5, 2023 07:18 ET

Cellectis | 6-K: Report of foreign private issuer (related to financial reporting)

Nov 17, 2023 16:56 ET

Cellectis | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Nov 17, 2023 16:35 ET

Cellectis | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-AstraZeneca Holdings B.V.(22.4%),AstraZeneca PLC(22.4%)

Nov 16, 2023 11:16 ET

Cellectis | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Nov 15, 2023 07:48 ET

Cellectis | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Caisse des Dépôts(9.7%),Bpifrance Participations S.A.(8.2%), etc.

Nov 13, 2023 15:04 ET

Cellectis | SC 13D: Statement of acquisition of beneficial ownership by individuals-AstraZeneca Holdings B.V.(22.4%),AstraZeneca PLC(22.4%)

Nov 9, 2023 17:07 ET

Cellectis | 6-K: Report of foreign private issuer (related to financial reporting)

Nov 9, 2023 16:01 ET

Cellectis | 6-K: Report of foreign private issuer (related to financial reporting)

Nov 6, 2023 16:35 ET

Cellectis | 6-K: Report of foreign private issuer (related to financial reporting)

Nov 6, 2023 16:30 ET